Skip to main content

Advertisement

Table 4 Contribution of LAP to the risk of all-cause mortality, independent of common CVD risk factors among men and women.

From: Predictive performances of lipid accumulation product vs. adiposity measures for cardiovascular diseases and all-cause mortality, 8.6-year follow-up: Tehran lipid and glucose study

  Men Women
  HR* (95% CIs) P-value HR* (95% CIs) P-value
Age (years) 1.09 (1.07-1.11) <0.001 1.14 (1.11-1.18) <0.001
Smoking 2.01 (1.32-3.04) 0.001 2.27 (0.69-7.50) 0.179
Premature history of CVD 0.58 (0.23-1.41) 0.228 1.16 (0.55-2.47) 0.692
Diabetes 1.52 (0.86-2.69) 0.151 1.30 (0.51-3.34) 0.579
Antihypertensive drug use 1.97 (1.31-2.98) 0.001 1.59 (0.92-2.74) 0.094
Systolic blood pressure (mmHg) 1.20 (1.03-1.40) 0.022 1.03 (0.80-1.32) 0.822
Intervention 0.69 (0.47-1.02) 0.061 1.10 (0.66-1.84) 0.708
Non-HDL-C (mmol.l-1) 0.94 (0.75-1.18) 0.595 0.86 (0.64-1.15) 0.295
HDL-C (mmol.l-1) 0.87 (0.69-1.08) 0.197 0.93 (0.71-1.22) 0.582
FPG (mmol.l-1) 1.19 (0.82-1.72) 0.366 0.67 (0.34-1.32) 0.253
2h-PCPG (mmol.l-1) 1.02 (0.79-1.31) 0.892 1.18 (0.86-1.63) 0.310
Ln LAP (cm.mmol.l-1) 0.74 (0.61-0.90) 0.003 0.88 (0.60-1.30) 0.530
  1. * For one SD increment in each continuous predictor, obtained from multivariate Cox proportional hazards regression model adjusted for age, smoking, systolic blood pressure, family history of premature CVD, diabetes, antihypertensive drug usage, HDL and non-HDL cholesterol, FPG, and 2h-PCPG , plus the TLGS intervention measures.
  2. CVD, cardiovascular disease; FPG, fasting plasma glucose; HDL-C, high density lipoprotein cholesterol; HR, hazard ratio; LAP, lipid accumulation product; Ln, naturally logarithmically transformed; 2h-PCPG, 2-hour post-challenge plasma glucose;